Focuses On Enhancements to Companies Immunotherapy Assay
FRANKLIN, Tenn. (PRWEB) November 01, 2018
Pierian Biosciences will present a poster with new data on ImmunoINTEL, at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer, to be held November 7-11, 2018 at the Walter E. Washington Convention Center in Washington, D.C. The poster, “ImmunoINTEL, a flow cytometry based platform that identifies and quantifies the most critical cell subsets and related functional potential in dissociated solid tumors,” (Poster #114) will be presented in Hall E on Saturday, Nov. 10 from 12:20 – 1:50 p.m. and 7:00 – 8:30 p.m.
“We are excited to present ImmunoINTEL at SITC and the opportunity to discuss with scientists the comprehensive, quantitative profiling of the tumor microenvironment and immune landscape,” says Norman Purvis, executive vice president of research and development for the company. “Our objective is to support biopharma, academic research and clinicians to better stratify patients and guide the selection of immunotherapies.”
About Pierian Biosciences
Based in Franklin, Tenn., Pierian Biosciences is a privately held life sciences company dedicated to profoundly changing the approach to treatment of patients with cancer and auto-immune diseases by providing information to enable healthcare providers to deliver on the promise of personalized medicine. The company’s advanced cytometric assay capabilities provide valuable information to aide pharmaceutical companies from early-stage drug development through clinical validation of new therapeutics. Pierian Bioscience technology includes the ImmunoINTEL and ChemoINTEL platforms designed with an aspiration to improve patient outcomes and lower health care costs. Pierian Biosciences has a laboratory in Franklin, Tenn. and business offices in Franklin, Tenn and the UK. For more information visit http://www.pierianbio.com.